Alnylam Pharmaceuticals | ALNY - Eps Gewinn Pro Aktie

Aktienkurs
330.34
Täglich Wechseln
11.49 3.60%
Monatlich
2.09%
Jährlich
41.81%
Q2 Prognose
309.25

Fiscal Kalender Aktuell Konsens Zuletzt Datum
FY2026Q1 Mar/2026 0.99 -0.01 Apr/30
FY2025Q4 Dec/2025 1.25 1.27 0.06 Feb/12
FY2025Q3 Sep/2025 2.90 0.27 -0.50 Oct/30
FY2025Q2 Jun/2025 0.32 -0.73 0.56 Jul/31
FY2025Q1 Mar/2025 -0.01 -0.94 -0.16 May/01




Eps Veränderung Datum
Acadia Pharmaceuticals USD 1.6 1.18 2025-12
Agios Pharmaceuticals USD -1.86 0.08 2025-12
Alnylam Pharmaceuticals USD 1.25 1.65 2025-12
Amgen USD 5.29 0.35 2025-12
Arrowhead Research USD 0.22 0.33 2025-12
BioCryst Pharmaceuticals USD 1.17 1.1 2025-12
BioMarin Pharmaceutical USD 0.46 0.34 2025-12
Incyte USD 1.8 0.46 2025-12
Ionis Pharmaceuticals USD -1.41 0.61 2025-12
Moderna USD -2.11 1.6 2025-12
Neurocrine Biosciences USD 1.88 0.29 2025-12
Novartis USD 1.54 0.48 2025-12
PTC Therapeutics USD -1.67 1.87 2025-12
Regeneron Pharmaceuticals USD 11.44 0.39 2025-12
Sangamo BioSciences USD -0.18 0.1 2024-06
Sanofi EUR -0.67 3.62 2025-12
Sarepta Therapeutics USD -3.58 3.45 2025-12
Takeda JPY 65.74 73.57 2025-12
Tectonic Therapeutic USD -1.03 0.01 2025-12
Ultragenyx Pharmaceutical USD -1.29 0.52 2025-12
Vertex Pharmaceuticals USD 5.03 0.23 2025-12
Xencor USD -0.09 0.01 2025-12